Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
02 juin 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
17 mai 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal...
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
16 mai 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New...
Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
12 mai 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial evaluating tegoprubart in IgA Nephropathy with...
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
09 mai 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
05 mai 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Travere Therapeutics Reports First Quarter 2022 Financial Results
05 mai 2022 16h01 HE
|
Travere Therapeutics, Inc.
Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society...
Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium
03 mai 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
18 avr. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
14 avr. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...